Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
BiOrion Technologies BV logo — We contribute to healthcare by developing novel radiopharmac...

BiOrion Technologies BV

We contribute to healthcare by developing novel radiopharmaceuticals for fibrotic diseases.

Founded 2007 The Netherlands The Netherlands 2 employees Biotechnology, Pharmaceutical

General Information

Company Name BiOrion Technologies BV
Founded Year 2007
Location The Netherlands The Netherlands +1
Employees 2
Industries Biotechnology, Pharmaceutical
Social

Get notified when BiOrion Technologies BV moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BiOrion Technologies BV

BiOrion Technologies BV is a Netherlands-based **biopharmaceutical** company founded in **2003**. The company specializes in developing combined PET-imaging diagnostics and targeted radionuclide therapeutics (theranostics) for fibrotic diseases and fibrotic cancers. BiOrion has differentiated itself from other companies by focusing on fibrogenesis, the activity involved in the formation of fibrotic tissue, rather than the conventional approach of focusing on collagen deposition. Their development of high-affinity binding single domain antibodies to PDGF-beta-receptors has proven to be a sensitive biomarker for fibrogenesis, providing a more reliable parameter to assess fibrosis. This approach has led to the creation of attractive non-invasive PET imaging tools for diagnosing fibrogenesis, as well as for determining the effectiveness of antifibrotic therapies, ultimately expediting the novel antifibrotic therapies' development. The company's innovative technology is not limited to fibrotic diseases but also extends to metastasizing cancers that rely on fibrotic stroma with similar biology to organ fibrosis. BiOrion's utilization of 68Gallium-labeled single domain antibodies for PET imaging of PDGF beta receptor-rich stroma tissue presents an opportunity for diagnosing these cancers. Furthermore, the potential to replace 68Gallium with 177Lutetium allows for the use of the single domain antibody as a targeted radiotherapeutic, especially beneficial for advanced colon cancer metastases to the liver. With its novel approach and promising applications in both fibrotic diseases and metastasizing cancers, **BiOrion Technologies** demonstrates potential for significant impact in the **biotechnology** and **pharmaceutical** industries.

Taxonomy: Radiopharmaceuticals, Fibrotic diseases, PET imaging, Theranostics, Single domain antibodies, PDGF-beta-receptors, Fibrogenesis, Antifibrotic therapies, Metastasizing cancers, 68Gallium, 177Lutetium, Colon Cancer, Pancreatic Cancer, Renal Fibrosis, Organ fibrosis

No funding data available for BiOrion Technologies BV yet.

Get notified when BiOrion Technologies BV raises funding

FAQ About BiOrion Technologies BV

We contribute to healthcare by developing novel radiopharmaceuticals for fibrotic diseases.
BiOrion Technologies BV was founded in 2007.
BiOrion Technologies BV is headquartered in The Netherlands.
BiOrion Technologies BV operates in the following industries: Biotechnology, Pharmaceutical.
BiOrion Technologies BV has approximately 2 employees.

We're actively collecting intelligence on BiOrion Technologies BV.

Track BiOrion Technologies BV to get notified

Don't just browse. Track.

Signal Tracker monitors BiOrion Technologies BV and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy